GlassScriptPhysician profile
Faseeh U Khaja
NPI 1053562678
$17,172.18
in general payments reported to CMS, 2019-2025
71 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $1,704 · 2021: $3,920 · 2022: $3,521 · 2023: $3,787 · 2024: $1,264 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,528 · Education: $197 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,528.40 |
| Education | $196.69 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,117.65 | 2019-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $1,128.63 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $974.34 | 2019-2025 | Darzalex, Erleada, Imbruvica |
| Lilly USA, LLC | $823.01 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $761.34 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $685.00 | 2019-2025 | |
| Seagen INC. | $650.45 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Daiichi Sankyo INC. | $612.13 | 2019-2024 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $543.55 | 2019-2024 | Opdivo |
| Amgen INC. | $541.34 | 2019-2023 | Lumakras |
| Incyte Corporation | $457.38 | 2019-2024 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $403.53 | 2019-2025 | Padcev, Xospata, Vyloy |
| Celgene Corporation | $377.94 | 2020-2023 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $354.90 | 2019-2025 | |
| Eisai INC. | $351.49 | 2019-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $327.59 | 2019-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $324.97 | 2019-2024 | Trodelvy |
| Genzyme Corporation | $298.77 | 2019-2023 | |
| Exelixis INC. | $263.22 | 2019-2024 | Cabometyx |
| Genentech USA, INC. | $260.41 | 2019-2025 | Kadcyla, Perjeta, Phesgo |
| Emd Serono, INC. | $231.55 | 2020-2025 | Bavencio |
| Takeda Pharmaceuticals U.S.A., INC. | $226.35 | 2019-2024 | Iclusig, Fruzaqla, Ninlaro |
| Array Biopharma INC | $196.23 | 2019-2025 | Lorbrena, Mektovi, Braftovi |
| Kite Pharma, INC. | $185.97 | 2021-2023 | Yescarta |
| Abbvie INC. | $184.28 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.53 | 2019-2023 | Gilotrif |
| Glaxosmithkline, LLC. | $168.43 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Servier Pharmaceuticals LLC | $158.68 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $154.23 | 2020-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $142.13 | 2021-2023 | Monoferric |
| Stemline Therapeutics INC. | $138.83 | 2023-2025 | Orserdu |
| Pharmaessentia USA Corporation | $134.59 | 2022-2024 | Besremi |
| Sobi, INC | $126.65 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $124.67 | 2022-2023 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $105.07 | 2019-2025 | Onivyde, Somatuline Depot |
| Puma Biotechnology, INC. | $94.44 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $92.99 | 2021-2023 | Fotivda |
| Sun Pharmaceutical Industries INC. | $83.90 | 2019-2023 | Odomzo, Yonsa |
| Alexion Pharmaceuticals, INC. | $81.84 | 2019-2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $81.76 | 2020-2024 | Pyrukynd |
| Myovant Sciences INC. | $65.96 | 2021-2022 | |
| Acrotech Biopharma INC. | $65.83 | 2023-2025 | Beleodaq |
| Amag Pharmaceuticals, INC. | $65.01 | 2019-2021 | |
| Kyowa Kirin, INC. | $63.16 | 2021-2023 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $61.56 | 2022-2023 | Libtayo |
| Morphosys, US INC. | $48.65 | 2021-2023 | Monjuvi |
| Deciphera Pharmaceuticals INC. | $43.57 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $43.19 | 2019-2023 | Tavalisse, Rezlidhia |
| Genmab U.S., INC. | $42.75 | 2023-2024 | Epkinly |
| Alnylam Pharmaceuticals INC. | $39.70 | 2023 | Givlaari |
| Epizyme, INC. | $34.51 | 2021 | |
| Sumitomo Pharma America, INC. | $34.39 | 2023 | Orgovyx |
| Heron Therapeutics, INC. | $33.85 | 2022-2023 | Cinvanti |
| Beigene USA, INC. | $33.75 | 2022-2025 | Brukinsa |
| Organon LLC | $32.83 | 2022-2023 | Ontruzant |
| Partner Therapeutics, INC. | $32.64 | 2019 | |
| Jazz Pharmaceuticals INC. | $28.74 | 2023 | |
| Ge Healthcare | $24.30 | 2021 | |
| Recordati_rare_diseases_inc. | $23.66 | 2023 | Sylvant |
| Shield Therapeutics INC | $22.25 | 2023 | Accrufer |
| Tersera Therapeutics LLC | $21.85 | 2022 | |
| Mirati Therapeutics, INC. | $20.10 | 2023 | Krazati |
| Sanofi-Aventis U.S. LLC | $18.89 | 2021 | |
| Novocure INC. | $17.73 | 2023 | Optune |
| Dova Pharmaceuticals | $17.64 | 2021 | |
| Cti Biopharma Corp. | $17.20 | 2023 | Vonjo |
| Shire North American Group INC | $16.81 | 2019 | |
| Blueprint Medicines Corporation | $14.88 | 2023 | Ayvakit |
| Myriad Genetic Laboratories, INC. | $14.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.69 | 2021 | |
| Taiho Oncology, INC. | $13.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faseeh Khaja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.